REGN2176-3
R2176-3-AMD-1417
Phase 2 small_molecule terminated
Quick answer
REGN2176-3 for Neovascular Age-Related Macular Degeneration is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Neovascular Age-Related Macular Degeneration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated